ERBB2 and breast cancer: Neratinib has been shown to be effective against BM in HER2-positive BC patients in several studies, especially a phase 2 TBCRC 022 trial(Freedman et al. 2016), which indicates that neratinib combined with capecitabine is effective against BCBM.